Quest Diagnostics Inc. vs Eli Lilly & Co.
DGX vs LLY — side-by-side comparison from reported financials. DGX leads 3, LLY leads 8 of 11 comparable metrics.
Quest Diagnostics Inc.
DGX · Healthcare
$230.97+0.07%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | DGX | LLY |
|---|---|---|
| Price | $230.97 | $1 177.20 |
| Market cap | $25.5B | $1.05T |
| Revenue (TTM) | $11.6B | $79.7B |
| Revenue growth | +3.7% | +31.7% |
| Net margin | 9.2% | 33.5% |
| Free cash flow | $1.35B | $18.2B |
| Net cash (debt) | ($4.75B) | ($35.2B) |
| 1-year price return | +27.3% | +37.6% |
| P/E | 24.0 | 41.6 |
| P/E vs own history (cheap-side %) | 5% | 88% |
| Dividend yield | 1.42% | 0.52% |
| Return on equity | 14% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 10 of 11 | 11 of 11 |
| Employees | 57,000 | 50,000 |
Full résumé-style profiles: DGX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.